SCYNEXIS, Inc.

SCYNEXIS, Inc.

Novel Anti-Infective Treatments

We are committed to delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections. We are developing Ibrexafungerp (formerly SCY-078), the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, for the treatment of several serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.

A Versatile Anti-Infective
News

Latest News

SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)

Read More

SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting

Read More

SCYNEXIS Appoints Business Development Veteran Philippe Tinmouth to its Board of Directors

Read More

SCYNEXIS Announces Closing of $35 Million Public Offering of Common Stock and Warrants

Read More

SCYNEXIS Announces Pricing of $35 Million Public Offering of Common Stock and Warrants

Read More

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

Read More

SCYNEXIS Commends the CDC for the Recognition of Candida auris as a New "Urgent Threat" in its Updated Report on Antibiotic Resistance Threats in the United States

Read More

SCYNEXIS Reports Third Quarter 2019 Financial Results and Provides Company Update

Read More

SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303)

Read More
View All News

FAQs

Click here for our list of Frequently Asked Questions

View FAQs
icon

Driven to Solve Global Health Threats and to Positively Impact the Lives of Patients

Our team strives to save and improve patients' lives. We are committed to developing and delivering innovative therapies to address difficult-to-treat and often life-threatening infections, and to transforming treatment paradigms for patients worldwide.

More About Us
icon

Our Innovative Antifungal Platform

Our lead candidate, Ibrexafungerp (formerly SCY-078), currently in Phase 2 clinical development, is a novel and structurally distinct glucan synthase inhibitor. It is the first representative of a new triterpenoid antifungal family.

Our Science Our Pipeline
icon

Success Backed by Strong Leadership

The innovation that drives our science and pipeline is a direct reflection of our leadership's passion for improving patients' lives. This leadership has a proven track record of drug development and commercialization, and deep antifungal expertise.

Leadership Board of Directors

SCYNEXIS, Inc.

Market/Symbol

Nasdaq: SCYX

Price

Change

52-Week Range

Daily Volume

Day Range

View Detailed Stock Info View Investor Relations View Investor Presentation

Email Alerts

Receive the latest news directly to your inbox

Sign Up